Kristel Dongallo
Nephrology · Los Angeles, CANPI 1619452869
Payments from drug & device makers
Across 120 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$735
- Lilly USA, LLC$604
- Vanda Pharmaceuticals Inc.$412
- Ardelyx, Inc.$278
- Mallinckrodt Hospital Products Inc.$246
- Amgen$231
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,779100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 18 | $735 |
| Lilly USA, LLC | 16 | $604 |
| Vanda Pharmaceuticals Inc. | 19 | $412 |
| Ardelyx, Inc. | 10 | $278 |
| Mallinckrodt Hospital Products Inc. | 6 | $246 |
| Amgen(2 entities) | 15 | $231 |
| Novo Nordisk | 5 | $209 |
| Aurinia Pharma U.S., Inc. | 3 | $183 |
| Fresenius USA Marketing, Inc. | 3 | $160 |
| GSK | 2 | $130 |
| Gilead | 1 | $121 |
| ANI Pharmaceuticals, Inc. | 4 | $115 |
| AstraZeneca | 5 | $86 |
| Novartis | 4 | $81 |
| Boehringer Ingelheim | 3 | $76 |
| Amarin Pharma, Inc. | 1 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| AbbVie | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Akebia Therapeutics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,788 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $126,086 |
| XphozahTenapanor Hcl | 35 | $99,625 |
| JardianceEmpagliflozin | 55 | $59,835 |
| TrulicityDulaglutide | 39 | $43,031 |
| JanuviaSitagliptin Phosphate | 30 | $36,526 |
| MounjaroTirzepatide | 26 | $25,758 |
| FarxigaDapagliflozin Propanediol | 13 | $10,718 |
| Repatha SureclickEvolocumab | 13 | $6,836 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $5,623 |
| Omega-3 Acid Ethyl Esters | 41 | $2,720 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,543 |
| Atorvastatin Calcium | 181 | $2,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,526 |
| Losartan Potassium | 133 | $1,490 |
| Metformin Hcl | 150 | $1,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $209 | $126,086119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $604 | $68,78965 claims |
| Boehringer IngelheimJardiance | $76 | $59,83555 claims |
| AstraZenecaFarxiga | $86 | $10,71813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.